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The development of multiple myeloma (MM) involves a series of genetic alterations and changes in the bone marrow micro-
environment, favoring the growth of the tumor and failure of local immune control. Quantitative and functional alterations in
CD4+ and CD8+ T cells have been described in MM. The balance between T regulatory cells (Treg) and T helper (Th) 17 cells
represents one essential prerequisite formaintaining anti-tumor immunity inMM. Tregs play an important role in the preservation
of self-tolerance and modulation of overall immune responses against infections and tumor cells. In MM patients, Tregs seem to
contribute tomyeloma-related immune dysfunction and targeting them could, therefore, help to restore and enhance vital immune
responses. Th17 cells protect against fungal and parasitic infections and participate in inflammatory reactions and autoimmunity.
The interplay of TGF-β and IL-6, expressed at high levels in the bone marrow of myeloma patients, may aﬀect generation of
Th17 cells both directly or via other pro-inflammatory cytokines and thereby modulate antitumor immune responses. A detailed
analysis of the balance between Tregs and Th17 cells seems necessary in order to design more eﬀective and less toxic modes of
immunotherapy myeloma which still is an uncurable malignancy.
1. Introduction
Multiple myeloma (MM) is a clonal B-cell malignancy char-
acterized by an accumulation of mature plasma cells in the
bone marrow, leading to bone destruction and failure of
normal hematopoiesis [1]. MM remains an incurable disease
even with the use of proteasome inhibitor bortezomib,
immunomodulatory drugs (thalidomide or lenalidomide),
and high-dose chemotherapy with autologous stem cell
transplantation (SCT), as part of first line therapy [2]. The
result of new US Food-and-Drug-Administration- (FDA-)
approved treatments in the past 7 years was a doubling of
patient survival from 3-4 to 7-8 years [2]. The paradigm of
drug development in MM has been targeting tumor cells in
their BM microenvironment [2].
The development of MM involves a series of genetic
alterations and changes in the BM microenvironment,
favoring the growth of the tumor and the collapse of local
immune control. Classically, MM is characterized by dif-
ferent stages of disease which, although not discernible in
every patient, progress frommonoclonal gammopathy of un-
certain significance (MGUS) though to active disease, a pla-
teau phase, relapsing disease, and finally, resistant disease [3].
Tumor cells and stromal cells interact via adhesion
molecules and cytokine networks to simultaneously promote
tumour cell survival, drug resistance, angiogenesis, and
disordered bone metabolism. A number of immunologically
active compounds are increased including transforming
growth factor-beta (TGF-β), IL-10, IL-6, and vascular
endothelial growth factor (VEGF). Cellular immune defects
in MM characterized by decrease in CD19 B cells, CD4, and
CD8 cells have been shown to negative correlate with sur-
vival, indicating a potential positive relationship between cel-
lular components of immune system and disease control [3].
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Accordingly, a significant impairment of T-cell function
has been described for patients with MM and patients with
MGUS. Although quantitative and functional alterations in
CD4 and CD8 cells have been demonstrated in MM and
MGUS, the biologic basis for these abnormalities remains
unclear [4].
CD4+CD25+FOXP3+ T regulatory (Treg) cells play an
important role in the maintenance of self-tolerance and the
modulation of overall immune responses against infections
and tumor cells. The abnormal Treg activity in MM patients
could, on the other hand, contribute to the myeloma-related
immune dysfunction targeting them that could, therefore,
help to restore and enhance vital immune responses [1].
T helper 17 (Th17) cells, a recently described CD4+ T-cell
subset, protect hosts against fungal and parasitic infections
and participate in inflammatory reactions and autoimmu-
nity [5]. The role of Th17 cells in tumor pathogenesis is still
not well defined. However, it seems possible that the balance
between Treg and Th17 cells is particularly essential for
maintaining homeostasis of antitumor immunity [5].
2. T Regulatory Cells
Natural Tregs develop during normal T-cell maturation in
the thymus and are responsible for tolerance against self-
antigens. They represent 5% to 10% of the CD4+ cells com-
partment in the peripheral blood [1]. Tregs express CD4 and
CD25 surface antigens as well as CTLA-4, GITR, CD103,
CD62L, CD69, CD134, CD71, CD54, and CD45RA. The sup-
pressive activity of Treg cells is associated with the overex-
pression of FOXP3, a member of the forkhead/winged helix
family, which acts as a transcriptional repressor [1].
Over the last few years, extensive literature has been pub-
lished on Tregs in the context of malignancy, infections, and
autoimmunity. Some studies have shown that the number of
CD4+CD25+ cells is increased in the peripheral blood and
bone marrow of MGUS and MM patients compared with
controls, suggesting that Tregs might play a role in under-
mining anti-infectious and antimyeloma immunity in this
hematological malignancy [3, 4].
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
is a coinhibitory molecule expressed by activated T cells and
a subset of regulatory T cells. CTLA-4 is of primary impor-
tance in maintaining immune homeostasis by downregulat-
ing T-cell signaling costimulatory pathways and contributing
to tolerance to self-antigens [6].
Two monoclonal antibodies against human CTLA-4, ipi-
limumab and tremelimumab, have been reported to elicit
objective and durable responses against tumor cells in clini-
cal trials. However, the functional impact of anti-CTLA-4
therapy on human immune responses to tumor antigens is
not yet fully understood [6].
Recent studies have conducted extensive immunologic
monitoring on a panel of patients selected from a large
cohort of metastatic melanoma patients treated with ipil-
imumab. Late onset of complete or partial remission was
noted, occurring after more than 12 weeks of treatment in
the majority of responding patients. Some patients demon-
strated overt progression before eventually responding or
showing disease stabilization during ipilimumab treatment.
This phenomenon of clinical progression followed by regres-
sion represents a response pattern atypical for cytotoxic
therapies. Unfortunately, while clinical trials have shown that
anti-CTLA-4 antibody therapy can have potent antitumor
eﬀects in a subset of metastatic melanoma patients, there
have been few studies of its functional impact on human
antigen-specific immune responses in other tumors, such as
MM [6].
3. Th17 Cells
Th17 cells diﬀerentiate in the presence of interleukin-6
(IL-6), IL-1, IL-21, and IL-23, with or without transforming
growth factor-beta (TGF-β), and produce IL-17 and IL-22.
Activated Th17 cells produce most of the IL-17, but CD8+
T cells, natural killer cells, and neutrophils also produce
variable amounts of IL-17. IL-17 induces expression of a
number of chemokines and cytokines including IL-6, TGF-β,
granulocyte-colony stimulating factor or granulocyte-ma-
crophage-colony stimulating factor, matrix metallopro-
teinase, and intercellular adhesion molecule-1 in a variety of
cell types, including bone marrow stromal cells [5].
One of the Th17-specific transcription factors is the
orphan nuclear receptor RORγ. Its specific isoform RORγt is
selectively expressed by Th17 cells and is regulated by STAT3.
Overexpression of RORγt promotes Th17 diﬀerentiation
when Th1 and Th2 development is inhibited. However, a
defective RORγt does not result in the complete abolishment
of Th17 diﬀerentiation or the total inhibition of autoimmu-
nity, suggesting that additional factors are involved [7].
A significant body of information has emerged support-
ing a critical role of immune cells (and associated cytokines)
as well as immune dysregulation in MM. The interplay of
TGF-β and IL-6, which are both expressed at high levels in
MM bone marrow, may aﬀect generation of Th17 cells both
directly or via other proinflammatory cytokines and thereby
modulate antitumor immune responses [5].
4. The Reciprocal Relationship between
Th17 Cells and Tregs
Treg and Th17 developmental programs are reciprocally
interconnected: upon TCR stimulation and a naive T cell can
be driven to express Foxp3 and become a Treg cell in the
presence of TGF-β. However, in the presence of TGF-β plus
IL-6 or IL-21, the Treg developmental pathway is abrogated,
and instead T cells develop into Th17 cells. Only the com-
bination of TGF-β plus IL-6/IL-21, but neither of them alone,
induces a robust production of IL-17 by naive T cells [8, 9].
Therefore, IL-6 plays a pivotal role in dictating the
balance between the generation of Tregs and Th17 cells. The
mechanism by which IL-6 and IL-21 act as switch factors
relies on the control of the Foxp3/RORγt balance [10, 11].
The reciprocal relationship between Tregs and Th17 cells
is further supported by the results obtained in IL-6 knockout
mice, which show a severe defect in the generation of
Th17 cells and increased numbers of Tregs in the peripheral
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repertoire. Thus, IL-6 may be the most crucial factor in med-
iating the conversion of Foxp3+ T cells into Th17 cells in
vitro and in vivo. The reexpression of the Th17 program in
Foxp3+ cells appears to be a two-step process that includes
downregulation of Foxp3 and release of RORγt from Foxp3-
mediated inhibition [11, 12].
5. Treg, Th17, and Multiple Myeloma
The role of Tregs in the biology of neoplastic diseases has
been the subject of a large number of recent studies. How-
ever, many in vitro or in vivo results remain contradictory.
For example, one study quantified numbers of Tregs in the
peripheral blood of normal individuals versus patients with
MGUS and MM and showed a significant reduction in the
number of Treg cells, measured by Foxp3 expression in the
patient group. These cells were described as dysfunctional
and unable to suppress the proliferation of T lymphocytes in
an organized manner [4]. On the other hand, another study
compared the number and function of Tregs in the periph-
eral blood and bone marrow of normal individuals and
patients with MM. They did not find a diﬀerence in the per-
centage of Treg cells between two compartments neither
between the two groups of individuals [1].
Many studies about Th17 cells in humans have focused
on patients with autoimmune diseases while there are very
few studies on cancer patients. In the case of MM, recent
publications have demonstrated increased number of Th17
cells in bone marrow in comparison with peripheral blood
with diﬀerent functional properties in these two compart-
ments. This increase in Th17 cells was not observed in the
bone marrow of patients with MGUS; however, numbers of
Th17 cells were the highest in MM patients with lytic bone
disease [13].
Our group has recently characterized the expression of
Treg- and Th17-related genes in total bone marrow aspirates
of MM and solitary plasmacytomas (SPs) to evaluate their
potential as therapeutic targets in this disease. Total bone
marrow seems to be a good source of samples for our study
because (1) it reflects the “real” tumor bone marrow T-cell
compartment, without manipulation of CD4 subpopula-
tions by FACS or magnetic sorting and (2) normal and
malignant plasma cells express no or very low levels of Foxp3
or ROR-γt (data not shown), suggesting that expression
of genes is representative for the respective CD4+ T cell
subpopulation [14, 15].
When expressions of Foxp3 andROR-γt genes were deter-
mined by quantitative real-time PCR (RQ-PCR) in bone
marrow aspirates of 37 newly diagnosed MM patients, 4
newly diagnosed SPs, and 5 healthy controls (allogeneic
transplant donors), Foxp3 was overexpressed in 72% of MM
cases. A 5.89-fold increase in Foxp3 expression was observed
in MM patients compared to controls (P = 0.047, Mann-
Whitney test) (Figure 1). On the other hand, MM patients
and controls showed equal levels of ROR-γt expression and
the diﬀerence between groups was not significant (Figure 2).
Also, SP bone marrow aspirates showed Foxp3 and ROR-γt
levels similar to controls. Overexpression of Foxp3 in MM
cases suggests an accumulation of immunosuppressive Tregs
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Figure 1: Relative expression (RE) of Foxp3 in bone marrow aspi-
rates of myeloma, solitary plasmacytomas, and normal controls.
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Figure 2: Relative expression (RE) of ROR-γt in bone marrow as-
pirates of myeloma, solitary plasmacytomas, and normal controls.
in the tumor environment and/or an immediate involve-
ment of this gene in the development and progression of
myeloma. Our results reinforce our hypothesis that thera-
peutic approaches that specifically target Foxp3-expressing
Tregs may provide more focused treatment strategies for
MM [14, 15]. Some studies have suggested that depletion of
Treg cells with a possible “reprogramming” of these cells to
proinflammatory Th17 cells could be a strategy of immu-
notherapy against tumors [16].
The immunomodulatory agents, such as lenalidomide,
currently used as standard fist therapy, have a multifunc-
tional action profile, with antiangiogenic activity, direct
eﬀects on myeloma cells, and alteration of the cytokine
milieu within the BM microenvironment. These drugs ex-
hibit potent costimulatory activity on primary T cells in vitro
and lead to an increased IL-2 and IFN-y production follow-
ing CD3 ligation. This eﬀect may contribute to the reduction
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of the ratio CD4/8 and to an increase of natural killer cyto-
toxic cells. Lenalidomide is more potent than thalidomide
in costimulating CD4 and CD8 T cells. Bortezomib is a
proteasome inhibitor with significant clinical activity inMM,
with also immunomodulatory with eﬀects on the survival
and function of lymphocytes and dendritic cells [3].
Further studies on the balance between Tregs and Th17
cells in malignancies such as MM are needed. Immunother-
apy using single strategies in MM have shown little clinical
eﬃcacy, and there is a belief that a combined approach is
required, as recently demonstrated in melanoma. In addi-
tion, results may further be improved by combining types
of new immunotherapy with standard immunomodulatory
agents (i.e., thalidomide, lenalidomide bortezomib) already
being used for the treatment of myeloma.
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